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SARS-CoV-2 Mpro is one of the enzymes essential for the replication process of the virus responsible for the
COVID-19 pandemic. This work is focused on exploring its proteolysis reaction by means of QM/MM
methods. The resulting free energy landscape of the process provides valuable information on the
species appearing along the reaction path and suggests that the mechanism of action of this enzyme,
taking place in four steps, slightly differs from that of other cysteine proteases. Our predictions, which
are in agreement with some recently published experimental data, can be used to guide the design of
COVID-19 antiviral compounds with clinical potential.Introduction
Novel severe acute respiratory syndrome – coronavirus 2 (SARS-
CoV-2) has been identied as the virus responsible for COVID-
19, the name designated to the global coronavirus 2019
pandemic disease emerged in late December 2019. At present
there are no vaccines or antiviral drugs available for the
prevention or treatment of COVID-19 infections. The main
coronavirus protease (SARS-CoV-2 Mpro, also called 3CLpro)
plays a key role in processing the polyproteins that are trans-
lated from the viral RNA in the replication of SARS-CoV-2 virus.
Thus, inhibiting the activity of this enzyme would block the viral
life cycle. In addition, a conserved feature of SARS-CoV-2 Mpro is
its specicity in cleaving proteins aer the Gln residue, a char-
acteristic observed in other coronavirus proteases but not in
human enzymes.1 Consequently, inhibitors of SARS-CoV-2 Mpro
shouldn't present toxic effects on humans, thus becoming an
excellent target to synthesize new anti-viral drugs. Within this
context, the existence of recently solved X-ray structures of
SARS-CoV-2 Mpro,1–3 opens the door for computer simulations
focused on understanding how this enzyme works, which canniversitat Jaume I, 12071 Castelló, Spain.
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10630assist in the design of new compounds with higher and more
selective inhibitory activity.
SARS-CoV-2 Mpro is a cysteine protease (CP) with an active
site catalytic dyad (Cys145/His41) similar to other CPs. It is
proposed that the imidazole group of His polarizes and acti-
vates the SH group of Cys to form a highly nucleophilic CysS/
HisH+ ion pair that would react with the substrate.4 In this
regard, according to our recent QM/MM study on the proteolysis
reaction catalyzed by the cruzain CP, the proton from the
protonated HisH+ is transferred to the N atom of the scissile
peptide bond aer the Cys attacks the carbonyl carbon atom of
the peptide.5 Aer this acylation step, the recovery of the
enzyme in the following deacylation stage would be assisted by
a water molecule activated by the His.
The present paper is focused on exploring the proteolysis reac-
tion catalyzed by SARS-CoV-2 Mpro by means of multiscale QM/MM
molecular dynamics (MD) simulations. This appears to be the rst
QM/MM study revealing the mechanism of action of SARS-CoV-2
Mpro at the atomistic level. The polypeptide Ac-Val-Lys-Leu-Gln-
ACC (ACC is the 7-amino-4-carbamoylmethylcoumarin uorescent
tag) was used as the substrate because rate constants have been
recently reported.6 Then, a valuable comparison between our
computational results and experimental data will allow the valida-
tion of our predictions. The structure of SARS-CoV-2 Mpro and
a schematic representation of the reaction are depicted in Fig. 1. As
shown, the full dimer will be considered for the simulations of the
proteolysis reaction taking place in one of the active sites.Computational methods
The molecular system was prepared based on the crystal
structure of wild type Mpro in complex with a peptidyl Michael
acceptor inhibitor (PDB ID 6LU7).2 The inhibitor was replaced
by the polypeptide Ac-Val-Lys-Leu-Gln-ACC by means of theThis journal is © The Royal Society of Chemistry 2020
Fig. 1 Structure of dimer SARS-CoV-2 Mpro and the substrate in an
active site (gold balls), together with the schematic representation of
the SARS-CoV-2 Mpro catalyzed reaction. The scissile peptide bond
between Gln5 and ACC is highlighted in orange.
Fig. 2 M06-2X:AM1/MM free energy profile of the proteolysis reaction
catalyzed by SARS-CoV-2 Mpro.































































































View Article OnlineDiscovery Studio Visualizer program.7 In particular, the side-
chains of the P1–P4 amino acids of the inhibitor were
mutated to the corresponding residues of the selected poly-
peptide while the ACC group was manually generated.
Once the fully solvated SARS-CoV-2 Mpro dimer was set up
and equilibrated by means of classical molecular dynamics
(MD) simulations (Fig. S1†), QM/MM free energy surfaces (FESs)
were obtained, in terms of potentials of mean force (PMFs), for
every step of the reaction using the umbrella sampling
approach8 combined with the weighted histogram analysis
method (WHAM).9 The semiempirical AM1 (ref. 10) method and
the density functional M06-2X11 were selected to describe the
QM sub-set of atoms (77 atoms, including ACC and Gln5 of the
substrate, the side chain of His41, full Cys145 residue and part
of the backbone of its preceding and posterior residues, Ser144
and Gly146, respectively. See Fig. S2†), while the protein and
solvent water molecules (71 819 atoms) were treated with the
AMBER12 and TIP3P13 force elds, respectively (see the elec-
tronic supplementary information† for details). It is important
to point out that despite limitations of some standard DFT
functionals for modelling sulfur nucleophiles with covalent
reactivity have been identied, M06-2X has been revealed to be
reasonably accurate.14 This is in good agreement with our
previous studies of the catalysis and inhibition of different
cysteine proteases carried out with this hybrid functional and
available experimental data.5,15,16Results and discussion
Analysis of the FESs (Fig. S3 and S4†) shows that both the
acylation and the deacylation reactions take place in a stepwise
manner (Fig. 2). Thus, according to the most favorable reaction
path, as depicted in Scheme 1, rst a proton is transferred from
Cys145 to His41 concomitant with the nucleophilic attack on
the carbonyl carbon atom of the peptide bond by the sulfur
atom of Cys145, thus leading to a thiohemiketal (THA) inter-
mediate, E-I1. Then, the cleavage of the peptide bond is assistedThis journal is © The Royal Society of Chemistry 2020by the proton transfer from the protonated His41 to the
nitrogen atom of the substrate, forming the acyl–enzyme
complex intermediate E-I2. Once the rst product of the reac-
tion, ACC, is released from the active site, an activated water
molecule attacks the carbonyl carbon atom of the Gln5 of the
peptide, concomitant with the proton transfer to His41; E-I3.
The covalent bond between Cys145 and the peptide in this
protonated THA intermediate is then broken to release the
second product species of the reaction in the last step. Details of
the active site in the key states of the reaction are depicted in
Fig. 3.
The full free energy landscape of the proteolysis reaction is
shown in Fig. 2 and is derived from the M06-2X:AM1/MM free
energy surfaces explored for the acylation and the diacylation
step (Fig. S3 and S4,† respectively). It is important to point out
that the analysis of the full reaction energy prole considered as
the sum of two consecutive processes relies on the idea that the
product of the acylation step, when ACC species is released, can
be considered as the initial state for the following diacylation
step. This is a good approximation if the exploration of the
energy landscape of multi-step reactions is carried out in terms
of free energy surfaces using statistical simulations. According
to the results, the rate limiting step of the acylation step is
determined by TSE:S/E-I1, with a free energy barrier of
19.9 kcal mol1 computed at 310 K. This value is in very good
agreement with the value that can be derived from the rate
constant reported by Rut et al., 19.4 kcal mol1.6 The kinetics of
the deacylation step is governed by the TSE-I2/E-I3, as in the
histidine-assisted thiomethanolysis of formamide and the
hydrolysis of the resulting thioester in solution.17 The resulting
free energy barrier, 22.8 kcal mol1, is close to the
26.6 kcal mol1 computed in our previous QM/MM study for the
deacylation step of the cruzain CP,5 even though in SARS-CoV-2
Mpro the reaction takes place in two steps through a protonated
THA E-I3, and a concerted path was located in cruzain. Anyway,
E-I3 and specially E-I1, must be considered as metastable
intermediates, considering the low energy barriers required for
their decomposition. In fact, as observed in Fig. 3, the peptide
bond is already elongated in TSE:S/E-I1 with respect to that of
E:S, although the proton transfer from His41 to the scissile
peptide bond is not involved in this transition state (H/NChem. Sci., 2020, 11, 10626–10630 | 10627
Scheme 1 Molecular mechanism of the proteolysis catalyzed by SARS-CoV-2 Mpro as deduced from QM/MM FESs.
Fig. 3 M06-2X/MM optimized structures of the key states of the
acylation (top panels) and deacylation (bottom panels): E:S, rate
determining TS of the acylation TSE:S/E-I1, TSE:S/E-I2, TSE-I2/E-I3, E-I2,
rate determining TS of the deacylation TSE:I2/E-I3, and TSE:S/E-I2.
Distances are in A.































































































View Article Onlinedistance ¼ 2.98 A). The E-I1 / E-I2 step can be dened as
a shoulder in the free energy prole thus suggesting an acyla-
tion reaction taking place through an almost concerted but very
asynchronous mechanism. Downhill trajectories starting from
TSE:S/E-I1 can end in E-I2 at 310 K. The concerted processes for
the acylation and the deacylation reactions have been also
explored and located (see optimized TSE:S/E-I2 and TSE-I2/E:P
structures in Fig. 3 and FESs in Fig. S5†) providing signicantly
higher activation energies; 25.6 and 40.6 kcal mol1, respec-
tively. Regarding the thermodynamics, a signicantly exergonic
process is obtained in both the acylation (18.7 kcal mol1) and
the deacylation (21.3 kcal mol1) steps.
Further insights into our results can be provided by
comparison with previous studies on other CPs. First, according
to the present results, the most stable protonation state of the
Cys145/His41 dyad in E:S (and in E:P) corresponds to that where
both residues are neutral (Fig. 3), in contrast with previous
computational studies of the proteolysis5 and inhibition15,16,18 of
other CPs. The Cys145/His41+ ion pair is located in high
energy regions of the FESs of the rst and last steps (Fig. S3†).
Analysis of the structures of E:S and those recently derived from10628 | Chem. Sci., 2020, 11, 10626–10630X-ray diffraction studies of SARS-CoV-2 Mpro in complex with
different inhibitors,1–3 suggests that the absence of a conserved
residue (Asp/Glu) interacting with the dN atom of His, thus
modulating its pKa, can be the origin of this singular behavior of
SARS-CoV-2 Mpro. The presence of a stable THA intermediate
during the acylation step in CPs is also a question of debate.
While this has been supported by X-ray diffraction studies,19 its
presence has been questioned by others,20 including ourselves.5
Moreover, previous attempts to explore the viability of the
inhibition of CPs, such as cruzain by peptidyl halomethyl
ketones,15 reveal that a stepwise mechanism involving the
formation of a THA intermediate was unsuccessful. Neverthe-
less, despite being a metastable intermediate as discussed
above, it appears that the presence of a THA (E:I1) in the active
site of SARS-CoV-2 Mpro is favored by strong hydrogen bond
interactions with an “oxyanion hole” formed by Gly143, Ser144
and Cys145 (Table S3†). A THA has been also detected in
a recent study of the inhibitory reaction of SARS-CoV-2 Mpro by
a-ketoamide inhibitors, stabilized by the same triad of resi-
dues.1 Regarding the deacylation step in CPs, there is also
controversy over its mechanism. Thus, while some authors have
proposed that it occurs in a concerted manner,5,21 others
support the presence of an intermediate similar to the proton-
ated THA intermediate E-I3.17 As in the case of E-I1, the “oxy-
anion hole” would stabilize E-I3 and favor a step-wise
deacylation process (Fig. S4 and Table S4†).
Finally, the specic protein–substrate interactions have been
analyzed, to provide further results to guide the design of
COVID-19 antiviral compounds. Fig. 4, together with Fig. S6 and
S7,† shows the main interactions between the individual frag-
ments of the substrate and the residues of each sub-site of the
binding pocket in the E:S non-covalent reactant complex. First
conclusion that can be derived from these results is that Gln is
the residue with the largest amount of favorable interactions
with the enzyme thus becoming the most important amino acid
for substrate recruitment. This conclusion, in agreement with
the specicity of SARS-CoV-2 Mpro in cleaving proteins aer the
Gln residue, can pave the way for future inhibitor design. It
appears that these interactions clearly dictate the favorable
orientation of the peptide in the active site for the proteolysis toThis journal is © The Royal Society of Chemistry 2020
Fig. 4 Protein-peptide interactions in E:S. (a) Definition of the protein subsites; (b) main average interaction energies (electrostatic plus Len-
nard–Jones, larger than 3 kcal mol1) between the individual fragments of the substrate and its binding pocket obtained as an average over 1000
structures from the AM1/MMMD simulation. (c) Structural representation of each binding pocket for the E:S structure optimized at the M06-2X/
MM level. Each fragment of the substrate is presented as spheres. Residues in yellow belong to the extended b-sheet motif, the residues of b-
turns are indicated in cyan, residues of the coil are in white and residues belonging to the 310-helix are indicated in blue.































































































View Article Onlinetake place, including the interaction with the catalytic Cys145
whose sulfur atom is well oriented towards the carbon atom of
the scissile peptide bond (Fig. 3). Interactions with Asn142 and
His163, the later through a strong hydrogen bond with the
oxygen atom of amide group of Gln5, appear to be relevant
(Table S3 and S4†). Asn142 also interacts with the previous
residue of the substrate and, to some extent, with the next
residue (ACC and Leu4, respectively). Interestingly, another
protein amino acid that interacts with these three fragments of
the peptide is Ser1, which belongs to the N nger of the other
protomer. This terminal group, located on the bottom of the S1
pocket establishes two strong hydrogen bond interactions with
the Glu166 of the protomer A. This linkage is possibly respon-
sible for the depth of S1 thus limiting the size of substituents at
this position in future inhibitor design. These results, apart
from supporting the fact that an individual SARS-CoV-2 Mpro
monomer is inactive, are in agreement with previous structural
studies on SARS-CoV Mpro in other coronaviruses that also
pointed out the relevance of Glu166, Phe140 and the N terminus
of the partner protomer in Mpro dimerization.22–24 Residues
Phe140, Leu141, Asn142, Glu166, His163, His172 and Ser1-B
were identied to be involved in the S1 subsite in the analysis
of the X-ray structure of SARS-CoV-2 Mpro covalently bound to
the N3 Michael acceptor inhibitor,2 and residues Phe140,
His163 and Glu166 in the X-ray structure of SARS-CoV-2 Mpro
covalently bound to a-ketoamide inhibitors.1 Other residues of
this and the rest of sub-sites identied in previous structural
studies do not appear to be involved in signicant stabilizing
interactions with the rest of amino acids of the peptide used inThis journal is © The Royal Society of Chemistry 2020the present study. In addition, even though it has been
demonstrated that the inhibition of CPs is dependent on the
interactions between the peptidic framework (the P2) of the
inhibitor and the S2 pocket of the enzyme,16,25 this is probably
not the case in SARS-CoV-2 Mpro where S2 is a small hydro-
phobic pocket without possibly strong hydrogen bond interac-
tions (Fig. 4), same as the S4 sub-site, as already pointed out in
previous structural studies.2,3 Finally, the S3 sub-site is
completely exposed to the solvent and the three signicant
interactions with the Lys3 of the substrate (Met165, Glu166 and
Gln189) are established with the peptide backbone atoms.Conclusions
We have described the SARS-CoV-2 Mpro catalytic proteolysis
mechanism at the atomistic level with high level DFT/MM
methods, including the structures of the different states
appearing along the most favorable reaction path. The pre-
dicted activation free energy of the rate limiting step is in very
good agreement with recently reported kinetic data using the
same peptidyl substrate, Ac-Val-Lys-Leu-Gln-ACC. Supported by
X-ray diffraction structures, our results suggest noticeable
differences between this and other CPs. They include the
protonation state of the catalytic His41/Cys145 dyad, the pres-
ence of a THA intermediate in the acylation state, and the
interactions that are established between the sub-sites of the
protein and the different fragments of a natural peptidyl
substrate. According to our results, it can be concluded that
SARS-CoV-2 Mpro is capable of catalyzing the proteolysisChem. Sci., 2020, 11, 10626–10630 | 10629































































































View Article Onlinereaction of peptide-like substrates by the combination of short
distance and long distance substrate–enzyme interactions,
basically in the S1 pocket.
Considering that the reaction of inhibition of SARS-CoV-2
Mpro by covalent (peptidyl) irreversible SARS-CoV-2 Mpro inhib-
itors is equivalent to the acylation step of the proteolysis, the
results presented in this study can be relevant for future
developments of drugs for COVID-19. Thus, these covalent
inhibitors must be designed to form a stable enzyme–inhibitor
complex similar to the product of the acylation step (E-I2).
Consequently, focus must be shied not only on obtaining an
exergonic process with low activation energy, but also on
avoiding its hydrolysis, which would be equivalent to our study
of the deacylation step (E-I2/ E:P). Then, apart from a reactive
warhead, the interactions between the rest of the inhibitor and
the different sub-sites of the binding pocket must be taken into
account, which can be guided by the results derived from the
present study.Author contributions
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